On 2 October 2009 Serbian Competition Authority (KZK) [1] issued an opinion concerning the Government's decision to reduce the number of medicines purchased by the medical institutions under the national health insurance scheme. KZK initiated its investigation following a complaint lodged by a law firm that alleged that the new list of the medicines approved under the national insurance scheme restricted competition on the market for pharmaceutical products. The complaint referred to the decision of the Government issued on 7 July 2009 in relation to the measures for stimulation of local drug manufacturing in times of economic recession. Following the initiative launched by the Serbian Chamber of Commerce [2] , the Government decided to support domestic drug
Share on
|
|
The Serbian Competition Authority advises the Government to review the list of medicines provided under the national health insurance scheme (Medicines provided under the national health insurance scheme)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
